FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)
Clinical trials for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) explained in plain language.
Never miss a new study
Get alerted when new FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) trials appear
Sign up with your email to follow new studies for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Hope for FSHD: experimental drug losmapimod moves to safety testing
Disease control TerminatedThis study tested a drug called losmapimod in people with facioscapulohumeral muscular dystrophy (FSHD), a rare disease that causes muscle weakness. The main goal was to see if long-term use of the drug is safe and tolerable. Participants were adults aged 18 to 65 who had already…
Matched conditions: FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)
Phase: PHASE2 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated May 17, 2026 08:19 UTC
-
Hope for FSHD: experimental drug losmapimod tested in major trial
Disease control TerminatedThis study tested a drug called losmapimod in 260 adults with facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes muscle weakness. Participants took either the drug or a placebo for 48 weeks to see if it could slow muscle decline. The trial was terminat…
Matched conditions: FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)
Phase: PHASE3 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated May 11, 2026 20:41 UTC